Effect of soluble PD-L1 in advance non-small cell lung cancer (NSCLC) patients treated with nivolumab or pembrolizumab
Latest Information Update: 04 Mar 2021
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer
- 15 Oct 2020 New trial record
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress